Betta Pharmaceuticals
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Economic and Technological Development Z...Phone Number
+86 57186130357Website
www.bettapharma.comRevenue
$365.4 MillionStock Symbol
300558Industry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Betta Pharmaceuticals
Betta Pharmaceuticals Co., Ltd. (SZ300558), established in 2003 in Hangzhou, China, is one of the leading Chinese pharmaceutical companies dedicated to develop and commercialize innovative oncology products to meet high unmet medical needs. With over 1,300 employees in Hangzhou and Beijing, Betta's development capabilities range from small-molecule to biologics discovery, clinical development, manufacturing, sales and marketing. Betta's leading product - icotinib (Conmana®), the first innovative oncology product developed and commercially launched by a Chinese pharmaceutical company - is one of the top selling targeted therapies treating non-small cell lung cancer patients in China, having achieved 1.55 billion RMB annual sales in 2019. Betta currently has two programs under NDA review by the NMPA, two programs under late-stage clinical development, eight programs under proof-of-concept clinical development, and multiple small-molecule and biologics programs under pre-clinical discoverRead more
Betta Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Betta Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Betta Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Betta Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Betta Pharmaceuticals had a recent Job posting/layoffs
Check out if Betta Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Betta Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Betta Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Betta Pharmaceuticals
Product Launch: Get notified when Betta Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Betta Pharmaceuticals
Find 3 more new buyers
Company Profile Activity
Activity Insights
Betta Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Betta Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Betta Pharmaceuticals.
Betta Pharmaceuticals Tech Stack
A closer look at the technologies used by Betta Pharmaceuticals
Betta Pharmaceuticals News & Media
China's Drug Farm secures $27m in first tranche of Series C | AVCJ
Drug Farm, a China and US-based developer of treatments for infection and immunological diseases, has raised USD27m in the first tranche of Series C funding led by Shanghai's YD Capital., Greater China, Expansion, Healthcare, China, BioVeda Capital, PharmaceuticalsEnsartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that Xcovery’s affiliate Betta Pharmaceuticals has received the National Medical Products Administration (NMPA)’s approval of ensartinib in China for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). Ensartinib has been previously approved for the second-line treatment of ALK-positive NSCLC in China in 2020. Ensartinib is a next generationAgenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals
LEXINGTON, Mass., July 28, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, today announced the closing of a $20 million equity investment, at $4.03 per share, by Betta...Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
LEXINGTON, Mass., June 22, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, announced today that it has entered into an agreement with Betta Pharmaceuticals (SZ300558), a...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Betta Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Betta Pharmaceuticals Co., Ltd. (SZ300558), established in 2003 in Hangzhou, China, is one of the leading Chinese pharmaceutical companies dedicated to develop and commercialize innovative oncology products to meet high unmet medical needs. With over 1,300 employees in Hangzhou and Beijing, Betta's development capabilities range from small-molecule... Read More
